Concepedia

Bicalutamide Monotherapy

Bicalutamide Monotherapy is a pharmacological treatment regimen in which bicalutamide, a nonsteroidal antiandrogen, is used as the sole therapeutic agent to suppress androgen receptor signaling in the management of prostate cancer.

319

Publications

19.2K

Citations

1.9K

Authors

659

Institutions

Publications per year

2017–2026

49

Parents

Publications

319

Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Ayca Gucalp, Sara M. Tolaney, Steven J. Isakoff et al. · Clinical Cancer Research · 2013 · 740 citations

, , +16

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

Mary‐Ellen Taplin, Glenn J. Bubley, Yoo‐Joung Ko et al. · PubMed · 1999 · 599 citations · Full text

, , +17

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

Takahito Hara, Jun‐ichi Miyazaki, Hideo Araki et al. · PubMed · 2003 · 427 citations

, , +17

Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

Zoran Čulig, Jens Hoffmann, Martin Erdel et al. · British Journal of Cancer · 1999 · 421 citations · Full text

, , +17

Structural basis for antagonism and resistance of bicalutamide in prostate cancer

Casey E. Bohl, Wenqing Gao, Duane D. Miller et al. · Proceedings of the National Academy of Sciences · 2005 · 418 citations · Full text

, , +17

1–5 of 319

Authors

1.9K

  1. PI
    Peter Iversen

    Rigshospitalet, Denmark

    19 publications · 1.9K citations

    17

    h-index

  2. TL
    Teuvo L.J. Tammela

    12 publications · 1.2K citations

    12

    h-index

  3. GJ
    Geert J.C.M. Kolvenbag

    Eastern Virginia Medical School, United States

    10 publications · 939 citations

    10

    h-index

  4. CT
    C. Tyrrell

    Plymouth Hospital, United Kingdom

    10 publications · 844 citations

    10

    h-index

  5. MS
    Mark S. Soloway

    University of Miami, United States

    9 publications · 449 citations

    9

    h-index

1–5 of 1.9K

Institutions

659

  1. AstraZeneca (United Kingdom)

    Cambridge, United Kingdom

    18 h-index

    48 publications

    4.4K citations

  2. Rigshospitalet

    Copenhagen, Denmark

    14 h-index

    30 publications

    5.7K citations

  3. Medical College of Wisconsin

    Milwaukee, United States

    13 h-index

    18 publications

    1.9K citations

  4. Memorial Sloan Kettering Cancer Center

    New York, United States

    13 h-index

    111 publications

    21.2K citations

  5. University of Copenhagen

    Copenhagen, Denmark

    12 h-index

    22 publications

    4.1K citations

  6. Dana-Farber Cancer Institute

    Boston, United States

    12 h-index

    52 publications

    17.5K citations

  7. Sunnybrook Health Science Centre

    Toronto, Canada

    11 h-index

    27 publications

    1.7K citations

  8. Harvard University

    Cambridge, United States

    11 h-index

    39 publications

    2.8K citations

1–8 of 659

Venues

  1. Journal of Clinical Oncology

    30 publications · 2.2K citations

    21

    h-index

  2. Urology

    20 publications · 1.3K citations

    18

    h-index

  3. The Journal of Urology

    18 publications · 1.7K citations

    17

    h-index

  4. The Prostate

    19 publications · 620 citations

    16

    h-index

  5. British Journal of Urology

    16 publications · 1K citations

    14

    h-index

1–5